Aiming to understand and enhance the effect of two promising anti-DIPG therapies, RUN DIPG are proud to support the work of Professor Javad Nazarian, at the Children’s National Hospital, Washington D.C, with an $80,000 commitment.
Oral therapies ONC201 and paxalisib (that will be studied in the upcoming international clinical trial ‘Combination Therapy for the Treatment of Diffuse Midline Gliomas’) will be the focus of Dr Nazarian’s work. His team will look to find ways to improve the rate and duration of response to these two drugs (previously been deemed safe for paediatric patients) by testing unique triple drug therapy approaches.
This work is an extension of past collaborative projects between Prof Nazarian and Associate Professor Matt Dun at the University of Newcastle, Hunter Medical Research Institute. Considered a field leader in DIPG/DMG research, we are looking forward to the insights A/Prof Nazarian and his team’s work will provide, so that more children may receive robust benefit from ONC201 and paxalisib therapies in their fight against diffuse midline glioma.
As always, these important projects cannot happen without the support and dedication of our runners, movers, followers and advocates – Team RUN DIPG, keep doing what you’re doing, together we will make the difference.